Health Diagnostics

Co-Diagnostics, Inc. Test Performance Demonstrated

Co-Diagnostics

Paper published in the Journal of Medical Microbiology utilizes Company’s test in rapidly deployable mobile molecular diagnostics

Co-Diagnostics, Inc.(Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the Journal of Medical Microbiology.

The study was performed using readily available open-source equipment and materials that could be successfully operated in regional clinical laboratories, many of which are not currently equipped for molecular diagnostics. When tested on clinical samples, the sensitivity and specificity of the Company’s test showed complete concordance with the comparison assay used in the study. The researchers also demonstrated an analytical sensitivity of 1010 viral copies per milliliter, which they found to be comparable to other tests used across Western Australia.

Dwight Egan, Chief Executive Officer of Co-Diagnostics, remarked, “We believe the results of this independent peer-reviewed paper further establishes the robustness, versatility, and quality of our Logix Smart COVID-19 diagnostic. Strong sales of our COVID-19 products continue domestically and abroad, illustrating the success of our business model as part of our continued commitment to making affordable molecular diagnostics available in settings ranging from high-throughput CLIA labs to remote locations across the world. Co-Diagnostics believes this study demonstrates that commitment, in addition to the advantages and adaptability of our CoPrimer™ technology.”

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.

Related posts

Ping An’s Health Diagnosis Imaging Model is a Breakthrough for AI

PR Newswire

Healthtech Co. Merck Will Present Data from a Phase II Trial

Business Wire

IBH Acquires Uprise, a World-class Digital Health Platform

Business Wire